PM
NEOS

Precept Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Precept Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-242,000
Closed -$2.01M – 97
2018
Q1 		$2.01M Buy
242,000
+176,000
+267% +$1.68M 0.84% 42
2017
Q4 		$673K Buy
+66,000
New +$633K 0.4% 47

Other funds holding NEOS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Precept Management's NEOS Position: Q2 2018 in Review

Precept Management sold out of Neos Therapeutics, Inc (NEOS) in Q2 2018, closing a stake of 242,000 shares — an estimated $2.01M sold.

Precept Management first reported a position in NEOS in Q4 2017 and held it in 2 quarters. The position peaked at $2.01M in Q1 2018. 73 funds tracked by Wall St. Rank hold NEOS as of Q2 2018.

  • Precept Management reported no remaining Neos Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
  • Precept Management sold 242,000 Neos Therapeutics, Inc shares in Q2 2018, an estimated $2.01M.
  • Precept Management first reported a position in Neos Therapeutics, Inc in Q4 2017 and held it in 2 quarters.
  • Precept Management's Neos Therapeutics, Inc position peaked at $2.01M in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2018.

Based on Precept Management's 13F filing for Q2 2018, filed 14 Aug 2018.